This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.

Read more at MarketWatch

Save story

Topics

Related

Here are 4 biotech stocks that could get a boost from Trump’s new regulatory climate
Business - MarketWatch - Yesterday
Bipolar disorder: how lithium as a treatment fell out of favour
World - The Guardian - November 9
Vietnam waits for major upgrade to its $200 billion stock market
Business - CNBC - October 28
Icahn Enterprises’ stock slides 14% as majority-owned CVR Energy suspends its dividend
Business - MarketWatch - October 29
What to know about a tropical depression that could develop into a late-season storm
Top stories - CBS News - 6 days ago
The First Crispr Treatment Is Making Its Way to Patients
Tech - Wired - 6 days ago
Disney is doubling its fleet of cruise ships. What that says about the company's strategy
Entertainment - Los Angeles Times - October 23

More from MarketWatch

BJ’s stock rises on first membership-fee increase in 7 years
Business - MarketWatch - 10 minutes ago
Jobless claims drop to 7-month low as economy plows ahead
Business - MarketWatch - 14 minutes ago
Deere’s earnings tumble but still blow past estimates as company offers soft guidance on weak demand
Business - MarketWatch - 31 minutes ago
Philadelphia Fed’s manufacturing gauge shows activity contracted in November
Business - MarketWatch - 32 minutes ago
Oil prices climb 2% on further escalation in Russia-Ukraine missile exchange
Business - MarketWatch - 37 minutes ago